Partnership strengthens clinical trial support


Share this:

Applied Pharmaceutical Innovation and IMPACT program at Innovate Calgary partner to provide companies with greater clinical trial expertise 

Applied Pharmaceutical Innovation (API) and the Integrated Management Platform to Accelerate Clinical Trials (IMPACT) program at Innovate Calgary have entered into a partnership to expand and fuel the growing world-class research in Alberta and foster innovation through collaboration.

By working together, API and IMPACT will be able to connect life sciences innovators to expertise that matches their needs. IMPACT focuses on helping health-tech or biomedical ventures conduct clinical trials and secure regulatory approvals for medical technologies and digital health technologies.

This will provide value-added services to researchers and innovators and continue to empower Alberta’s strength in life sciences research and development. “API has broad-based support to enable the growth of companies across the life sciences,” said Paramita Chaudhuri Basu, Director of Programs and Ecosystem Development at API, “Our work with Innovate Calgary has led to some wonderful collaborations and expansion of technical capacity for innovators”

“This exciting partnership will provide clinical and regulatory support in cutting-edge medical device technology and innovative pharmaceutical drug development. By pooling our resources and expertise, companies and start-ups will benefit from a comprehensive healthcare solution that meets their evolving needs for approvals, market adoption and scaling” Crespo’o Ndiabamoh, Associate Director of IMPACT.

“Clinical trials are complex and the team of venture navigators at IMPACT have the tools and expertise in place to support innovators,” said Juliana Weber, Director of Clinical Affairs with API. “Together, our teams can provide valuable guidance on clinical trial design, regulatory affairs, and other aspects of product development.  This allows innovators to focus on their core mission and accelerate bringing their products to market.”

Together, the partners will share intelligence and combine expertise in clinical trial design and execution, manufacturing regulatory affairs, and quality management systems.

This partnership further enhances the goal of building a robust life sciences industry in Alberta. Currently the life sciences industry generates $1 billion in revenues and employs over 12,000 people in Alberta. 

About the partners:

INCA {id} Final Logo
Impact CMYK FullColour Horizontal

Resident at the Life Sciences Innovation Hub, University of Calgary, the IMPACT program is a pioneer in life sciences and biomedical industries, supporting those needing guidance and financial fulfillment in conducting clinical trials to secure regulatory approval for their new health-related inventions. The IMPACT Venture Navigators work closely with their partners to design, execute, and report on their pre-market clinical trials.

API is an industry-led not-for-profit organization that provides life sciences  technology development capacity for innovative companies to commercially produce their intellectual property within Canada. Since its incorporation in 2018 API has grown to over 60 staff supporting more than 43 SMEs, scaleups and spinoffs. API has helped life sciences companies increase their market capitalization by over $500 million with commercialization, incubation, and scale-up capacity across Alberta for innovators in the life sciences, including pharmaceuticals, vaccines, natural health products, medical devices, and more.